01 1Hubei Enoray Biopharmaceutical
01 1ENOXAPARIN SODIUM USP
01 1China
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2018-05-16
Pay. Date : 2018-02-20
DMF Number : 32021
Submission : 2017-12-13
Status : Active
Type : II
20
Hubei Enoray Biopharmaceutical Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA.
One of their notable products is ENOXAPARIN SODIUM USP, with a corresponding US DMF Number 32021.
Remarkably, this DMF maintains an Active status since its submission on December 13, 2017, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of May 16, 2018, and payment made on February 20, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II
